Moreover, pre-clinical models of glioma, and metastases to the liver, lymph nodes or lungs that are vessel co-option-dependent, showed that blocking both the angiopoietin and VEGF pathways was more effective compared to the inhibition of VEGF alone [116,117]. The gene discussed is VEGFA; the disease is central nervous system cancer.